TrialCancer2019

A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.

Martin H Voss et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.